Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 6/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6917401 | 1.00 | CA2 (0.41) | CA2CA1CA7CTSKCYP2D6 | |
| SCHEMBL385450 | 1.00 | CA2 (0.41) | CA2CA1CA7CTSKCYP2D6 | |
| SCHEMBL4671380 | 0.92 | CYP2D6 (0.45) | CA2CA1CA7CTSKCYP2D6 | |
| SCHEMBL2104058 | 0.92 | CYP2D6 (0.45) | CA2CA1CA7CTSKCYP2D6 | |
| SCHEMBL4671387 | 0.92 | CYP2D6 (0.45) | CA2CA1CA7CTSKCYP2D6 | |
| SCHEMBL2727644 | 0.91 | CA2 (0.43) | CA2CA1CA7CTSKCYP2D6 | |
| SCHEMBL211542 | 0.91 | CA2 (0.43) | CA2CA1CA7CTSKCYP2D6 | |
| SCHEMBL211543 | 0.91 | CA2 (0.43) | CA2CA1CA7CTSKCYP2D6 | |
| SCHEMBL23487152 | 0.87 | CTSK (0.43) | CA2CA1CA7CTSKCYP2D6 | |
| SCHEMBL20786413 | 0.87 | CYP2D6 (0.38) | CA2CA1CA7CTSKCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0145875-A2 | Gamma-aminobutyric acid transaminase inhibitors and processes for their preparation | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-06-26 | — | — | EP | claimed |
| US-20230173079-A1 | Conjugate Molecules | DIVERSE BIOTECH, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2021249417-A1 | HETEROCYCLIC COMPOUND AND DERIVATIVE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2021-12-16 | — | — | WO | disclosed |
| WO-2021076197-A1 | CONJUGATE MOLECULES | DIVERSE BIOTECH, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2020263888-A1 | CANNABINOID CONJUGATE MOLECULES | DIVERSE BIOTECH, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-8580823-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580823-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| CN-103351389-A | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARM LLC | 2013-10-16 | — | — | CN | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008036247-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| CN-101142215-A | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARM LLC (US) | 2008-03-12 | — | — | CN | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-5719141-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0145875-B1 | GAMMA-AMINOBUTYRIC ACID TRANSAMINASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-02-19 | — | — | EP | disclosed |
| US-4824974-A | Synthesis for the preparation of 4-amino-4,5-dihydro-2-furancarboxylic acid | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-04-25 | — | — | US | disclosed |
| US-4588825-A | Intermediates for the synthesis of 4-amino-4,5-dihydro-2-furancarboxylic acid | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0145875-A2 | Gamma-aminobutyric acid transaminase inhibitors and processes for their preparation | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173079-A1 | Conjugate Molecules | CNR2, CNR1, MAG | CA2 2973/4885CA1 1515/4885CA7 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.